Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN   1:34:49 PM EDT
589.25
-2.90 (-0.49%)
Products

FDA Accepts Libtayo For Priority Review For Advanced Cervical Cancer

Published: 09/28/2021 11:09 GMT
Regeneron Pharmaceuticals, Inc. (REGN) - FDA Accepts Libtayo® (cemiplimab-rwlc) for Priority Review for Advanced Cervical Cancer.
Regeneron Pharmaceuticals Inc - Target Action Date for FDA Decision is January 30, 2022.
Regeneron Pharmaceuticals - Sbla is Also Being Reviewed Under FDA's Project Orbis Initiative.
Regeneron Pharmaceuticals Inc - Additional Global Regulatory Submissions Are Planned, Including in European Union (eu) by End of 2021.